ArticleThe European respiratory journal2010
Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis?
Article in The European respiratory journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 58 citations in OpenAlex.
- Burden of Pulmonary Arterial Hypertension (PAH) on Patients Admitted for Asthma: A Nationwide Analysis, 2016-2020.Cureus · 2025Article
- Targeting type-2 inflammation in pulmonary hypertension: lessons from a novel model.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Rap1A Modulates Store-Operated Calcium Entry in the Lung Endothelium: A Novel Mechanism Controlling NFAT-Mediated Vascular Inflammation and Permeability.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Article
- Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA.The European respiratory journal · 2023Article
- Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life.Nature communications · 2022Article
- Article
- Single-Cell RNA-Sequencing Reveals the Active Involvement of Macrophage Polarizations in Pulmonary Hypertension.Disease markers · 2022Article
- Role and Diagnostic Performance of Host Epigenome in Respiratory Morbidity after RSV Infection: The EPIRESVi Study.Frontiers in immunology · 2022Observational
- Comorbidities and laboratory parameters associated with SARS-CoV-2 infection severity in patients from the southeast of Mexico: a cross-sectional study.F1000Research · 2022Article
- Functional assessment of the right ventricle in patients with bronchial asthma of various severity.Postepy dermatologii i alergologii · 2021Article
- Resistin family proteins in pulmonary diseases.American journal of physiology. Lung cellular and molecular physiology · 2020Review
- World Trade Center Dust induces airway inflammation while promoting aortic endothelial dysfunction.Toxicology and applied pharmacology · 2020Article
- miRNAs in Lung Development and Diseases.International journal of molecular sciences · 2020Review
- The role of CaScientific reports · 2020Article
- Plexiform Arteriopathy in Rodent Models of Pulmonary Arterial Hypertension.The American journal of pathology · 2019Review
- Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice.The Journal of experimental medicine · 2018Article
- Pruning of the Pulmonary Vasculature in Asthma. The Severe Asthma Research Program (SARP) Cohort.American journal of respiratory and critical care medicine · 2018Article
- Sudden maternal hypoxemia during elective cesarean section in a woman with placenta previa.Clinical case reports · 2017Article
- Mesenchymal stem cell-conditioned media suppresses inflammation-associated overproliferation of pulmonary artery smooth muscle cells in a rat model of pulmonary hypertension.Experimental and therapeutic medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Although largely distinct and seemingly unrelated, asthma and pulmonary arterial hypertension (PAH) have important pathological features in common, including inflammation, smooth muscle contraction and remodelling. We hypothesised that these common features could be explained by one shared mechanism of pathogenesis: activation of the transcription factor NFAT (nuclear factor of activated T-cells). If this concept is validated, it could lead to the introduction of novel therapeutic strategies against both lung disorders. In several experimental models, airway remodelling is accompanied by remodelling of smaller pulmonary arteries, validating the hypothesis of their similar pathogenesis. In addition, lungs of vasoactive intestinal peptide (VIP) knockout mice express airway hyperresponsiveness with airway inflammation and PAH with vascular remodelling, with both sets of pathological findings being reversible with VIP treatment. Preliminary data suggest that absence of the VIP gene leads to activation of the calcineurin-NFAT pathway, and that VIP is probably a physiological inhibitor of this pathway. Enough evidence exists to support the views that asthma and PAH share important pathological features, probably related to NFAT activation, and that VIP may be a physiological modulator of this mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.